GlassScriptPhysician profile
Nathan Jerome Rudometkin
NPI 1225128994
$1,192.90
in general payments reported to CMS, 2019-2025
11 companies · $669 in 2025
The $669 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.17 · 2022: $204 · 2023: $148 · 2024: $150 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933 · Entertainment: $34.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.85 |
| Entertainment | $34.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $274.68 | 2022-2025 | Vabysmo |
| Astellas Pharma US INC | $229.98 | 2023-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $214.74 | 2022-2025 | Eylea Hd |
| Abbvie INC. | $147.45 | 2022-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $127.76 | 2023-2025 | Syfovre |
| Amgen INC. | $40.29 | 2025 | Tepezza |
| Bausch & Lomb Americas INC. | $36.04 | 2025 | Miebo, Xiidra |
| Harrow Eye, LLC | $35.61 | 2025 | Vevye |
| Optos, INC. | $34.06 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Mallinckrodt Hospital Products INC. | $30.12 | 2025 | Acthar |
| Eyepoint US, INC. | $22.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Rudometkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.